Beatty Liver and Obesity Research Program

The research portfolio includes development of diagnostic tests (called biomarkers) to predict an individual’s predisposition to disease and targeted therapies for those affected.

The urgency for this obesity research is clear. Obesity-related liver disease currently affects about 30 percent of the U.S. population and that number is expected to climb dramatically in the years ahead. Our investigators are shedding new light on this insidious disease and sharing their findings on the world stage. In the last few years, they have presented at numerous international conferences and written articles which have been published in important peer-reviewed journals. Such exposure adds to the body of research and positions Inova as a major player in this critical area of investigation.

The Beatty Liver and Obesity Research Program's objective is to generate innovative discoveries and pursue the development of novel biomarkers for the diagnosis and treatment of several important diseases by implementing personalized medicine protocols.